Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
EphB6 crosslinking results in costimulation of T cells
Hongyu Luo, … , Yulian Wu, Jiangping Wu
Hongyu Luo, … , Yulian Wu, Jiangping Wu
Published October 15, 2002
Citation Information: J Clin Invest. 2002;110(8):1141-1150. https://doi.org/10.1172/JCI15883.
View: Text | PDF
Article Aging

EphB6 crosslinking results in costimulation of T cells

  • Text
  • PDF
Abstract

Research Article

Authors

Hongyu Luo, Guang Yu, Yulian Wu, Jiangping Wu

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Activation marker expression and proliferation of EphB6+ versus EphB6– T...
Activation marker expression and proliferation of EphB6+ versus EphB6– T cells. All experiments were performed more than three times and were reproducible. Representative results are shown. T cells were first purified from PBMCs with negative selection using MACS beads. The T cells were cultured in medium for 48 hours to achieve high EphB6 expression, and then stained with biotin-conjugated anti-EphB6 mAb followed by PE-streptavidin. The cells with the highest 30% and lowest 30% EphB6 fluorescence intensity were sorted by high-speed flow cytometry. (a) The top row shows EphB6 expression of sorted EphB6+ and EphB6– T cells. The lower two rows show CD25 and CD69 expression after stimulation with solid-phase anti-CD3 mAb alone (0.2 μg/ml during coating) or with anti-CD3 plus anti-CD28 mAb (4 μg/ml during coating) for 24 hours after sorting. Solid lines represent EphB6+ T cells and dotted lines represent EphB6– T cells. The percentages represent cells in CD25+ or CD69+ regions after deducting background staining (isotypic mAb). For the last panel, region A represents all CD69-positive cells, and region B represents cells with high CD69 intensity. (b) Sorted EphB6+ (solid line) and EphB6– (dotted line) cells were cultured in wells coated with anti-CD3 and anti-CD28, as described above, for an additional 1–3 days. Their thymidine uptake was measure for the last 8 hours of culture.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts